


Antibody platform for potent and specific complement activation

Few therapeutic antibodies developed today induce potent complement activation. We have developed a technology that potently activate the complement system on specific antigens. Proof of principle data suggest superiority over closest prior art. The technology can be transferred to other antigens and is broadly applicable.



Technology Description

Therapeutic antibodies used in cancer treatment often rely on activating different parts of the immune system for optimal efficiency.

Only a subset of currently licensed antibodies activates the complement system and complement may thus represent a severely under-exploited mechanism for clearance of cancer cells but also pathogenic microorganisms.

A new antibody based technology to potently and specifically activate the complement system on target cells has been invented by Aarhus University.

Intellectual Property Rights

All rights are owned by Aarhus University. We are currently initiating a patent application.

Team



Nick Stub Laursen
Assistant Professor
Department of Molecular
Biology and Genetics



Dennis Vestergaard Pedersen
Postdoc
Department of Molecular
Biology and Genetics



Gregers Rom Andersen
Professor
Department of Molecular
Biology and Genetics

Current State

Current data are for lung and breast cancer.

- Proof-of-concept *in vitro* experiments with a validated cancer antigen show potent complement activation and cell killing.
- We are currently testing different antibodies against other validated cancer antigens using the same technology.

Business opportunity and Call to action

We are seeking partners within the field of therapeutic antibodies to assist in validating and directing the development of the technology.

Contact information

Morten Holmager
Business Development Manager
Mobile: +45 9350 8718
E-mail: holmager@au.dk

